Bausch Health

Diversified pharma / GI (Salix)

BHC · NYSE · Canada

Share price · BHC

$8.73+1.80 (+25.97%) 3M

close as of 2026-11-18 · 24h delayed · vol 7.1M (1.8x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when BHC's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 29 Oct 2026+28.8%
  2. 28 Oct 2026+9.7%
  3. 4 Aug 2026-8.0%
  4. 31 Jul 2026+14.3%
  5. 30 Jul 2026+28.8%
  6. 26 Jun 2026-9.8%
  7. 17 Jun 2026-4.0%
  8. 11 May 2026-6.6%
  9. 10 Apr 2026+3.9%
  10. 23 Jan 2026-10.0%

Share of unusual movement by asset

For each asset, the share of BHC's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
brodalumab (Siliq)
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—0%
Other company news (earnings, financing, releases naming no asset)—40%
Sessions with no dated event—60%

Assets

(15 total)
15Total Assets
13Approved
1Phase 3 / Filed
1Phase 1–2 / Early
6Diseases
Quick filter:
Showing 15 of 15 assets
Target & Modality
Approved
AminosalicylateSmall molecule
Inflammatory Bowel Disease
Ulcerative Colitis
brodalumab(Siliq)
Approved
IL-17 receptor AMonoclonal antibody
Psoriasis
Approved
Glucocorticoid receptorSmall molecule
Inflammatory Bowel Disease
Ulcerative Colitis
Approved
Glucocorticoid receptorSmall molecule
Inflammatory Bowel Disease
Ulcerative Colitis
Approved
GABA-A receptorSmall molecule
Epilepsy
Approved
5-HT1D receptorSmall molecule
Migraine
Approved
5-HT1D receptorSmall molecule
Migraine
Approved
Glucocorticoid receptorSmall molecule
Psoriasis
Approved
Glucocorticoid receptor + retinoic acid receptorSmall molecule
Psoriasis
Approved
AminosalicylateSmall molecule
Inflammatory Bowel Disease
Ulcerative Colitis
Approved
Mechanism not establishedSmall molecule
Epilepsy
Approved
Rifamycin AntibacterialSmall molecule
Travelers' Diarrhea
Verteporfin(Visudyne)
Approved
Benzoporphyrin-derivative photosensitizer for photodynamic therapySmall molecule
Age-Related Macular Degeneration
Phase 3
Rifamycin AntibacterialSmall molecule
Indication not yet linked
Phase 2
S1P receptorSmall molecule
Inflammatory Bowel Disease
Ulcerative Colitis, Crohn's Disease

Discontinued programmes (1)

Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

January 2026Topline resultRifaximin SSDPhase 3 RED-C programmes (NCT05071716, NCT05297448): both failed their primary endpoints
15 September 2022Withdrawalbalsalazide disodium (Giazo)FDA withdraws approval of NDA 022205 (Federal Register 2022-17534)
US, FDA · Source ↗

Financial reports

Quarterly & interim (18)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$2.9B$141M$2.5B—$814M operating cash flowreport ↗
View 17 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$2.9B$173M$1.8B—$670M operating cash flowreport ↗
2026-Q1$2.5B$163M$1.3B—report ↗
2025-Q4$2.8B$161M$1.3B—report ↗
2025-Q3$2.7B$166M$1.3B—report ↗
2025-Q2$2.5B$159M$1.7B—report ↗
2025-Q1$2.3B$143M$1.1B—report ↗
2024-Q4$2.6B$163M$1.2B—report ↗
2024-Q3$2.5B$146M$719M—report ↗
2024-Q2$2.4B$156M$595M—report ↗
2024-Q1$2.2B$151M$755M$64M$211M operating cash flowreport ↗
2023-Q3$2.2B$153M$780M$378M$282M operating cash flowreport ↗
2023-Q2$2.2B$156M$588M—$206M operating cash flowreport ↗
2023-Q1$1.9B$143M$531M$201M$154M operating cash flowreport ↗
2022-Q3$2.0B$133M$497M—-$1.3B operating cash flowreport ↗
2022-Q2$2.0B$127M$1.9B$145M$123M operating cash flowreport ↗
2022-Q1$1.9B$127M$2.5B$69M-$63M operating cash flowreport ↗
2021-Q3$2.1B$121M$1.9B—$564M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$10.3B$629M$1.3B—report ↗

Bausch Health reported full-year 2025 revenue of $10,266M, up 6.7% YoY, with R&D spend of $629M, up 2.1% YoY, cash and equivalents of $1,310M, and net income attributable to Bausch Health of $157M. The company also reported consolidated adjusted EBITDA attributable to Bausch Health of $3.54 billion for the year, up 7%.

For 2026, the company guided to revenues of $10.625–$10.875 billion, adjusted EBITDA of $3.875–$4.000 billion, and adjusted operating cash flow of $1.200–$1.275 billion. Pipeline updates included FDA Breakthrough Therapy Designation for larsucosterol and initiation of its Phase 3 trial in January 2026, Australian approval of the Fraxel FTX laser system, and RED-C Phase 3 studies that did not achieve their primary endpoint. Key disclosed events included the completion of the Shibo aesthetics distribution acquisition in China and $9.6 billion in total 2025 refinancing, including a $1.7 billion debt exchange in the fourth quarter.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$9.6B$616M$1.2B—report ↗
2023-FY$8.8B$604M$947M—report ↗
2022-FY$8.1B$529M$564M—report ↗
2021-FY$8.4B$465M$582M—report ↗

Insider transactions

Open-market activity, trailing 12 months: 1 purchase ($15.6M), 5 sales ($507K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-09-30WECHSLER AMY B · directorAward / grant1,179$5.83$7KForm 4
2026-09-30LEUNG SANDRA · directorAward / grant5,789$5.83$34KForm 4
2026-09-30Paulson John · directorAward / grant10,720$5.83$62KForm 4
2026-08-19Lenar Aimee J. · President, US PharmaOpen-market sale36,827$7.03$259KForm 4
2026-07-17Lenar Aimee J. · President, US PharmaTax withholding5,260$4.83$25KForm 4
2026-07-15Lenar Aimee J. · President, US PharmaTax withholding23,395$4.89$114KForm 4
2026-07-14LEE STEVEN HYOSIG · SVP, Controller & CAOTax withholding3,125$4.75$15KForm 4
2026-06-30LEUNG SANDRA · directorAward / grant6,845$4.93$34KForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 226 reporting institutions held 232.6M shares ($1.2B, 62.2% of shares outstanding).

#InstitutionSharesValue
1PAULSON & CO. INC.73,255,869$395.6M
2GOLDENTREE ASSET MANAGEMENT LP34,665,731$187.0M
3ROYAL BANK OF CANADA11,363,498$61.4M
4NOMURA HOLDINGS INC8,986,372$48.5M
5HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND8,000,000$43.2M
6VANGUARD CAPITAL MANAGEMENT LLC7,403,759$40.0M
7MFN Partners Management, LP6,000,000$32.4M
8GEODE CAPITAL MANAGEMENT, LLC4,228,871$31.4M
9Kohlberg Kravis Roberts & Co. L.P.5,235,000$28.3M
10GOLDMAN SACHS GROUP INC5,207,966$28.1M
11Hudson Bay Capital Management LP5,000,000$27.0M
12ING GROEP NV5,000,000$27.0M
13Nuveen, LLC3,798,957$20.5M
14DIMENSIONAL FUND ADVISORS LP3,604,818$19.5M
15MACQUARIE GROUP LTD3,250,000$17.6M